Dr Reckamp on the Landscape of Current and Emerging ADCs in NSCLC

Karen L. Reckamp, MD, MS, discusses current and emerging antibody-drug conjugates in lung cancer in addition to highlighting the development of patritumab deruxtecan and telisotuzumab vedotin.

Related Keywords

Karenl Reckamp , ,Sinai Medical Center ,Lung Institute ,Clinical Research ,Division Of Medical Oncology ,Sinai Samuel Oschin Comprehensive Cancer Institute ,Medical Oncology ,Cedars Sinai Medical Center ,Lung Cancer ,Nsclc ,T Dxd ,Her3 Dxd ,Elisotuzumab Vedotin ,Antibody Drug Conjugates ,